COMPUTER-ASSISTED DRUG DESIGNING OF TRIAZOLE DERIVATIVE OF NOSCAPINE AS TUBULIN-BINDING ANTICANCER DRUG
Keywords:Noscapine, Triazole, Tubulin heterodimer, Molecular docking, Surface generalized born
Objective: Microtubule-interfering drugs are commonly used to treat malignant disorders owing to indispensable role of this cytoskeletal element. These drugs include paclitaxel, docetaxel, and the Vinca alkaloids; however, owing to their non-selective action and overpolymerizing effects, these chemotherapy drugs are confounded by complications with serious toxicity (particularly, peripheral neuropathies, gastrointestinal toxicity, myelosuppression, and immunosuppression) (by taxanes) or depolymerizing effects (by Vincas) on microtubules. Thus, there is urgent need to explore novel tubulin-binding agents that are significantly effective and comparatively less toxic compared to currently available drugs for the treatment of human cancer. The current study focuses fusion of two novel anticancer compounds with low toxicity, i.e., noscapine and triazole to generate a new ligand derivative.
Methods: Using computer-aided drug designing approach and molecular docking, molecular interaction of these derivatives with Î±Î²-tubulin heterodimer was confirmed and investigated by molecular docking along with dynamics simulation.
Results: A greater affinity of the newly designed ligands for binding to tubulin was predicted. The predictive binding free energy (Gbind,pred) of these derivatives (ranging from âˆ’10.5178 to âˆ’16.8473 kcal/mol) based on linear interaction energy method with a surface generalized born continuum salvation model showed improved binding affinity with tubulin as compared to the lead compound. natural Î±-Noscapine (âˆ’5.505 kcal/mol). The binding energy of ligand determined using LigX, i.e., MM/GBVI was found to be âˆ’23.208 kcal/mol.
Conclusion: We found that designed derivative compounds have better efficacy as compared noscapine and triazole.
Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: Cell cytoskeleton in cancer metastasis. Br J Pharmacol 2014;171:5507-23.
van Vuuren RJ, Visagie MH, Theron AE, Joubert AM. Antimitotic drugs in the treatment of cancer. Cancer Chemother Pharmacol 2015;76:1101-12.
Idanpann-Heikkila JE, Jalonen K, Vartiainen A. Evaluation of the antitrussive effect of noscapine and codeine on citric acid cough in guines-pigs. Acta Pharmacol Toxicol 1967;25:333-8.
Eagle H, Foley G. Cytotoxicity in human cell cultures as a primary screen for the detection of anti-tumor agents. Cancer Res 1958;18:1017-25.
Lettre H. Synergists and antagonists of mitotic poisons. Ann NY Acad Sci 1954;58:1264-75.
Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998;95:1601-6.
El-Sayed WA, Flefel EM, Morsy E. Anticancer and antimicrobial activities of some synthesized pyrazole and triazole derivatives. Der Pharm Chem 2012;4:23-32.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.